BIAF Stock Overview
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
bioAffinity Technologies, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.00 |
| 52 Week High | US$3.62 |
| 52 Week Low | US$0.95 |
| Beta | 0 |
| 1 Month Change | 40.85% |
| 3 Month Change | 93.55% |
| 1 Year Change | 46.34% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -63.86% |
Recent News & Updates
Shareholder Returns
| BIAF | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 6.0% | -2.5% | -3.2% |
| 1Y | 46.3% | -3.7% | 19.3% |
Return vs Industry: BIAF exceeded the US Biotechs industry which returned -3.7% over the past year.
Return vs Market: BIAF exceeded the US Market which returned 19.3% over the past year.
Price Volatility
| BIAF volatility | |
|---|---|
| BIAF Average Weekly Movement | 23.2% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BIAF's share price has been volatile over the past 3 months.
Volatility Over Time: BIAF's weekly volatility has increased from 16% to 23% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 14 | Maria Zannes | www.bioaffinitytech.com |
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level.
bioAffinity Technologies, Inc. Fundamentals Summary
| BIAF fundamental statistics | |
|---|---|
| Market cap | US$34.54m |
| Earnings (TTM) | -US$7.94m |
| Revenue (TTM) | US$2.53m |
13.6x
P/S Ratio-4.4x
P/E RatioIs BIAF overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIAF income statement (TTM) | |
|---|---|
| Revenue | US$2.53m |
| Cost of Revenue | US$1.74m |
| Gross Profit | US$791.62k |
| Other Expenses | US$8.73m |
| Earnings | -US$7.94m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.69 |
| Gross Margin | 31.26% |
| Net Profit Margin | -313.41% |
| Debt/Equity Ratio | 0% |
How did BIAF perform over the long term?
See historical performance and comparison